{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for icosapent root_names_stdName in Standardized Name (approximate match)
Status:
Possibly Marketed Outside US
Source:
21 CFR 346
(1964)
Source URL:
First approved in 1964
Source:
21 CFR 346
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 343
(2007)
Source URL:
First approved in 1941
Source:
NDA206544
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
NCT04487912: Phase 4 Interventional Withdrawn Breast Cancer
(2020)
Source URL:
Class:
POLYMER
Status:
Withdrawn
Source:
Polidexide [UK]
Source URL:
Class:
POLYMER
Status:
US Approved Rx
(1954)
Source:
NDA009190
(1954)
Source URL:
First approved in 1954
Source:
NDA009190
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M020
(2022)
Source URL:
First approved in 2022
Source:
M020
Source URL:
Class:
G1 SPECIFIED SUBSTANCE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class:
G1 SPECIFIED SUBSTANCE
Status:
Possibly Marketed Outside US
Source:
ANDA210465
(1995)
Source URL:
First approved in 1995
Source:
ANDA210465
Source URL:
Class:
G1 SPECIFIED SUBSTANCE
Status:
Possibly Marketed Outside US
Source:
NDA209777
(1950)
Source URL:
First approved in 1950
Source:
NDA209777
Source URL:
Class:
G1 SPECIFIED SUBSTANCE
